Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 AlteredExpression BEFREE In conclusion, this meta-analysis indicates that FGFR2 overexpression is associated with poor pathological features and prognosis in patients with GC. 30662521

2019

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE Fibroblast growth factor receptor-2 (<i>FGFR2</i>) gene is amplified in up to 15% of patients with gastric cancer (GC). 31258762

2019

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 AlteredExpression BEFREE The FGFR2-inhibitory activity of PRO-007 was confirmed in genetically modified GC cell lines. 31396354

2019

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE Amplification of fibroblast growth factor receptor2 (FGFR2) has been regarded as a druggable target in gastric cancer (GC). 30044964

2018

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE The aim of the present study was to explore the effects of miR‑494 and FGFR2 in regulation of cancer‑initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2‑positive gastric cancer. 29786108

2018

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 AlteredExpression BEFREE FGFR2 was shown to be markedly overexpressed in GC tissues and was correlated with a high risk of lymph node metastasis, late clinical stage, and poor prognosis. 30355943

2018

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE Recently, targeting FGFR2 has drawn attention as a form of gastric cancer therapy, and FGFR-selective inhibitors have shown promising efficacy in clinical studies. 30045926

2018

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE Fibroblast growth factor receptor (FGFR2) has been proposed as a target in gastric cancer. 28852882

2018

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 AlteredExpression BEFREE There was no interaction between FGFR2 expression and patient survival outcomes in stage II/III gastric cancer. 29434882

2018

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE The in vivo models established using SGC cell lines are expected to serve as a useful tool for the development of drugs such as FGFR2 inhibitors, TβR inhibitors, and CXCR1 inhibitors, which might be promising as SGC treatments. 29876827

2018

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 GeneticVariation BEFREE In tumor cell lines displaying molecular alterations in potential nintedanib targets, the inhibitor demonstrates direct antiproliferative effects: in the NSCLC cell line NCI-H1703 carrying a PDGFR<i>α</i> amplification (ampl.); the gastric cancer cell line KatoIII and the breast cancer cell line MFM223, both driven by a FGFR2 amplification; AN3CA (endometrial carcinoma) bearing a mutated FGFR2; the acute myeloid leukemia cell lines MOLM-13 and MV-4-11-B with FLT3 mutations; and the NSCLC adenocarcinoma LC-2/ad harboring a CCDC6-RET fusion. 29263244

2018

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE In the current study, we aimed at revealing the function of DDX6 in HER2 and FGFR2 related human gastric cancer (GC) by using clinical samples and GC cell lines. 29987267

2018

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE Using a three-dimensional organoid tissue model, we functionally validated the metastatic potential of an FGFR2 amplification in gastric cancer. 28629429

2017

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. 28122360

2017

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 AlteredExpression BEFREE As a well-defined antagonist in FGFR2-induced RAS/ERK activation, ectopic expression of sprouty (SPRY) family was reported in several kinds of cancers except gastric cancer. 28002800

2017

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 AlteredExpression BEFREE Subgroup analysis revealed that high fibroblast growth factor receptor 2 expression was also associated with poor prognosis of gastric cancer, hepatocellular carcinoma, and esophageal cancer, but not correlated with pancreatic cancer. 28618942

2017

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE Our findings suggest that FGFR2 amplification is a relevant therapeutic target in GC with peritoneal carcinomatosis. 28501555

2017

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE However, multivariate analysis indicated that FGFR2 amplification was not an independent prognostic factor for OS (HR=1.42, 95% CI: 0.77-2.61, p=0.261).Although FGFR2 amplification is associated with poorer OS, it does not appear to be an independent prognostic predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine and platinum chemotherapy. 27802183

2017

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. 27230412

2016

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer. 27245147

2016

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE In conclusion, CD44 and FGFR2 maintain stemness in gastric cancer by differentially regulating c-Myc transcription. 27107424

2016

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE Similar results were obtained in additional GC cell lines with amplification of MET or the FGF receptor FGFR2 MKN45 murine xenograft experiments demonstrated the antitumor activity of M-COPA in vivo Taken together, our results offer an initial preclinical proof of concept for the use of M-COPA as a candidate treatment option for MET-addicted GC, with broader implications for targeting the Golgi apparatus as a novel cancer therapeutic approach. 27197184

2016

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 AlteredExpression BEFREE Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer. 26516773

2015

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 Biomarker BEFREE FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry. 25972329

2015

Entrez Id: 2263
Gene Symbol: FGFR2
FGFR2
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.600 GeneticVariation BEFREE Overall, 78% of GC cases harbored one clinically relevant GA or more, with the most frequent alterations being found in TP53 (50%), ARID1A (24%), KRAS (16%), CDH1 (15%), CDKN2A (14%), CCND1 (9.5%), ERBB2 (8.5%), PIK3CA (8.6%), MLL2 (6.9%), FGFR2 (6.0%), and MET (6.0%). 25882375

2015